Skip to content

Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas

Clinical Study of the Utility of a Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04055688
Enrollment
20
Registered
2019-08-14
Start date
2019-08-15
Completion date
2021-02-23
Last updated
2022-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor, Glioma

Keywords

Orbeye Surgical Microscope, fluorescence-guided surgery, 5-ALA

Brief summary

5-ALA and the Orbeye surgical microscope are U.S. Food and Drug Administration (FDA) approved products. For this study, the Orbeye microscope imaging system is being used with special filters to visualize 5-ALA fluorescence. The FDA currently permits the use of these filters. The purpose of this study is to collect medical information before, during, and after standard treatment in order to better understand how to make this type of procedure accessible to patients. This study is also being conducted to determine if use of the Orbeye equipped with these special filters improves the ability of the surgeon to remove brain tumors.

Interventions

DEVICEOrbeye surgical videomicroscope

The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.

5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.

Sponsors

Olympus Corporation
CollaboratorINDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must have a suspected or biopsy-proven high-grade glioma (World Health Organization grade II or IV), new or recurrent. * Indication for craniotomy for removal of a suspected or recurrent brain tumor * Karnofsky Performance Scale \>/- 60%

Exclusion criteria

* Prophyria, hypersensitivity to porphyrins * Renal insufficiency as defined per protocol * Hepatic insufficiency as defined per protocol * Existing pregnancy (to be checked by a pregnancy test if of child-bearing age. * Nursing women or women using inadequate contraception

Design outcomes

Primary

MeasureTime frameDescription
Compare Visualized Fluroescence within brain tumorsSurgery day one6 tissue samples will be obtained intraoperatively for each patient and assessed for 5-ALA visualization (strongly positive.weakly positive/negative). Tissue samples will be submitted for pathological assessment to determine whether tumor cells are present or absent. Visualization results will be evaluated against the pathology results (gold standard) to determine the sensitivity, specificity, positive predictive value and negative predictive value for 5-ALA visualizations with use of the ORBEYE system.

Secondary

MeasureTime frameDescription
Volume of Residual tumorup to 48 hours after surgeryResidual tumor volume will be identified in post surgical MRI scans. Extent of resection will be compared to preoperative MRI scans.
Number of Patients experiencing Adverse EventsUp to 16 days after surgeryPatients will be assessed for neurological and general side effects/toxicities 7-16 days after surgery.

Other

MeasureTime frameDescription
Post Surgery QuestionnaireSurgery day oneSurgeons will complete a questionnaire after each surgery to assess the visual experience of using the ORBEYE during the surgical procedure. The questionnaire asks about the superiority of the ORBEYE system compared to conventional binocular microscope, using a scale of 1-5, 1 being strongly agree and 5 being strongly disagree.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026